Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:55:54 EDT Thu 14 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:AGEN from 2025-05-15 to 2026-05-14 - 40 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-05-11 08:45U:AGENNews ReleaseAgenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
2026-05-04 16:30U:AGENNews ReleaseAgenus to Provide First Quarter 2026 Financial Report and Corporate Update
2026-04-21 10:00U:AGENNews ReleaseAgenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
2026-04-21 08:00U:AGENNews ReleaseAgenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
2026-04-17 16:43U:AGENNews ReleaseAgenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
2026-04-03 07:30U:AGENNews ReleaseAgenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
2026-04-01 07:30U:AGENNews ReleaseAgenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
2026-03-26 16:52U:AGENNews ReleaseAgenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
2026-03-17 16:40U:AGENNews ReleaseAgenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
2026-03-16 07:30U:AGENNews ReleaseAgenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
2026-03-10 07:30U:AGENNews ReleaseAgenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
2026-03-04 16:30U:AGENNews ReleaseAgenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
2026-02-19 15:15U:AGENNews ReleaseAgenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL
2026-02-09 13:00U:AGENNews ReleaseAgenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
2026-01-21 07:30U:AGENNews ReleaseAgenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
2026-01-20 18:24U:AGENNews ReleaseAgenus to Host First 2026 Stakeholder Webcast
2026-01-15 07:01U:AGENNews ReleaseAgenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
2026-01-12 07:30U:AGENNews ReleaseFrance Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
2025-12-23 08:05U:AGENNews ReleaseAgenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
2025-12-12 10:31U:AGENNews ReleaseGI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
2025-11-19 16:01U:AGENNews ReleaseAgenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
2025-11-18 08:41U:AGENNews ReleaseAgenus Appoints Dr. Jose Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC
2025-11-10 07:30U:AGENNews ReleaseAgenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
2025-11-05 13:47U:AGENNews ReleaseAgenus to Provide Corporate Update and Third Quarter 2025 Financial Report
2025-10-17 08:00U:AGENNews ReleaseAgenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
2025-10-16 07:48U:AGENNews ReleaseAgenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
2025-09-09 07:43U:AGENNews ReleaseFrance Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
2025-09-05 08:52U:AGENNews ReleaseAgenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-26 09:37U:AGENNews ReleaseUpdate: Agenus Aug 27 Stakeholder Webcast-Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight
2025-08-19 07:30U:AGENNews ReleaseAgenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
2025-08-11 07:30U:AGENNews ReleaseAgenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
2025-07-31 07:30U:AGENNews ReleaseAgenus to Provide Corporate Update and Second Quarter 2025 Financial Report
2025-07-25 12:46U:AGENNews ReleaseAgenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
2025-07-07 08:55U:AGENNews ReleaseAgenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
2025-06-17 07:30U:AGENNews ReleaseAgenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
2025-06-17 07:30U:AGENNews ReleaseAgenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
2025-06-10 13:30U:AGENNews ReleaseAgenus Announces Virtual Annual Shareholders Meeting
2025-06-03 07:00U:AGENNews ReleaseAgenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US
2025-05-30 07:30U:AGENNews ReleaseAgenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer
2025-05-15 10:40U:AGENNews ReleaseAgenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025